Anti-BAFF receptor CAR-T cell therapy (City of Hope National Medical Centre/PeproMene Bio)

Home About Us Our Team Our Publications Science BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS Pipeline Investors Contact Us Our Team Our Publications BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS Home About Us Our Team Our Publications Science BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS Pipeline Investors Contact Us Our Team Our Publications BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS Home About Us Our Team Our Publications Science BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS Pipeline Investors Contact Us Our Team Our Publications BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS Home About Us Our Team Our Publications Science BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS Pipeline Investors Contact Us Our Team Our Publications BAFFR CAR-T CELLS BAFF-R BiTEs BAFFR CAR-NK CELLS To find the article on the web: Click here IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted for oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting. The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who failed prior CD19-directed therapy or presented with CD19-negative disease. Interim results from the Phase 1 dose-escalation studies (NCT04690595, NCT05370430) support BAFF-R as a differentiated target designed to overcome CD19 antigen escape while maintaining durable activity and low toxicity. r/r B-NHL Safety:PMB-CT01 demonstrated an exceptionally favorable tolerability profile. No Grade ˃1 Cytokine Release Syndrome (CRS) and no Grade ˃1 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Efficacy:All the first 7 patients achieved a Complete Response (CR) at 1–3 months post-infusion, including those previously treated with CD19 CAR T therapy and those with CD19-negative disease. Durability:Remissions have remained ongoing for up to 32+ months (median 17 months) at data cutoff. r/r B-ALL Efficacy:Four of six enrolled patients achieved an undetectable Minimal Residual Disease (MRD-) Complete Remission (CR) High-Risk Population:Three of the four responders were CD19-negative at enrollment. All three successfully transitioned to allogeneic hematopoietic cell transplant (HCT) with curative intent. Safety:No Dose-Limiting Toxicities (DLTs) were observed. Only one patient experienced Grade 2 CRS, with no Grade 3 CRS reported. “The consistent and durable activity seen across both B-ALL and B-NHL, particularly in patients who have exhausted CD19 CAR T options or present with CD19-negative disease, strongly supports BAFF-R as a highly effective and safe alternative target,” said Hazel Cheng, Ph.D., COO of PeproMene Bio. “These data highlight PMB-CT01’s potential to address critical unmet needs in high-risk relapsed disease.” ASH 2025 Oral Presentations Abstract Title: BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r/r B-cell lymphomas… Abstract: abs25-7079Date/Time: December 6, 2:45 PMPresenter: Elizabeth Budde, M.D., Ph.D. Abstract Title: BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r/r B-cell ALL patients…Abstract: abs25-2035Date/Time: December 8, 11:00 AMPresenter: Ibrahim Aldoss, M.D. (Dates/times are placeholders.) About PMB-CT01 PMB-CT01 is a first-in-class BAFF-R–targeted autologous CAR T cell therapy. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape. PMB-CT01 is being evaluated in Phase 1 trials for r/r B-NHL and r/r B-ALL. Forward-Looking Statements This press release contains forward-looking statements subject to risks and uncertainties, including risks related to clinical development, regulatory outcomes, therapeutic potential, and commercialization. PeproMene Bio undertakes no obligation to update forward-looking statements except as required by law. Media/Investor Contact:Hazel Cheng, Ph.D.PeproMene Bio, Inc.Hazel.Cheng@pepromenebio.com SOURCE PeproMene Bio, Inc. Sitemap About Us Science Pipeline Investors Contact Us About Us Science Pipeline Investors Contact Us Address PeproMene Bio. Inc 15375 Barranca Pkwy. Suite A213 Irvine, CA 92618 Contact info Steve Lee T. 949-418-8860 E. info@pepromenebio.com COPYRIGHT © 2017-2026 PeproMene Bio. Inc. ALL RIGHTS RESERVED

Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive $6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. Patients with relapsed/refractory follicular lymphoma will be included in the expansion phase of PeproMene Bio's PMB-102 Phase 1 study evaluating BAFF-R targeting CAR T cells (PMB-CT01) in adult patients with r/r B-cell Non-Hodgkin Lymphoma (B-NHL). IRVINE, Calif., Dec. 19, 2024 /PRNewswire/ -- PeproMene Bio, Inc. (PMB) has announced an $11M investment from the Institute for Follicular Lymphoma Innovation (IFLI) to support the clinical development of PMB-CT01 (BAFF-R CAR T cell therapy) in patients with relapsed or refractory (r/r) follicular lymphoma. The investment includes $6M USD upfront and an additional $5M USD in conditional tranched funding. Building on the promising results of PMB's Phase 1 study, the expansion phase will now include patients with r/r follicular lymphoma, further evaluating the safety and efficacy of BAFF-R targeting CAR T cells in heavily pretreated patients. BAFF-R CAR T cell therapy was developed by City of Hope to provide an alternative or follow-on treatment option for the significant number of patients with B-cell malignancies that relapse after receiving standard of care medication including commercial CD19 CAR T cell therapy. "There is a significant unmet need for effective treatments following CD19 CAR T therapy that are both safe and effective in heavily pretreated patients," said Hazel Cheng PhD., COO of PMB. "We are deeply committed to the ongoing scientific and clinical development of this potentially promising new cell therapy in r/r follicular lymphoma and other types of B cell malignancies." "It's truly encouraging that all six patients with non-Hodgkin lymphoma treated with PMB-CT01 have demonstrated 100% CR rate and only low-grade treatment emergent adverse events, specifically Grade 1 CRS and Grade 1 ICANS)," said Elizabeth Budde M.D., PhD., the trial's principal investigator and associate professor of hematology at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. "Most of the trial participants relapsed after CD19 CAR T therapy and/or presented with CD19 negative tumor. PMB-CT01 could therefore offer a viable therapeutic option for patients facing this challenging scenario. It is also noteworthy that BAFF-R CAR T might outperform the FDA approved CD19 CAR T cell therapies given its consistently favorable balance of efficacy-safety." "PMB-CT01 shows tremendous potential in enhancing patient outcomes for Non-Hodgkin Lymphomas, particularly follicular lymphoma," stated Michel Azoulay, M.D., CMO of IFLI. "We are thrilled to back PeproMene Bio, Inc. in their exploration of PMB-CT01 for follicular lymphoma patients." For more information on PeproMene Bio, Inc. visit pepromenebio.com, and for more information on the Institute for Follecular Lymphoma Innovation visit i-fli.org. About PMB-CT01 PMB-CT01 is a first-in-class, BAFF-R targeted, autologous CAR T cell therapy. BAFF-R (B-Cell Activating Factor Receptor), a member of the tumor necrosis factor (TNF) receptor superfamily, is the main receptor for BAFF and is expressed almost exclusively on B cells. Since BAFF-R signaling promotes normal B-cell proliferation and appears to be required for B-cell survival, tumor cells are unlikely to escape therapy via loss of the BAFF-R antigen. This unique characteristic makes BAFF-R CAR T therapy a highly promising option for treating B-cell malignancies. The BAFF-R CAR was constructed using anti-BAFF-R single-chain fragment variable (scFv) antibodies and second-generation signaling domains CD3ζ and 4-1BB. Our research has demonstrated that BAFF-R CAR T cells effectively kill human lymphomas and leukemias both in vitro and in animal models. PeproMene Bio has licensed intellectual property relating to PMB-CT01 from City of Hope. About PeproMene Bio PeproMene Bio, Inc. is a clinical-stage biotech company based in Irvine, California and is focused on the clinical development of novel therapies to treat B-cell malignancies and autoimmune disorders. PeproMene's lead candidate, PMB-CT01 (BAFFR-CAR T cells) is currently being investigated to treat relapsed and refractory B-cell non-Hodgkin lymphoma (B-NHL; NCT05370430), B-cell, acute lymphoblastic leukemia (B-ALL; NCT04690595) in phase 1 clinical trials. PeproMene Bio is also developing BAFFR Bispecific T Cell Engager and BAFFR-CAR NK cells. About iFLI About The Institute for Follicular Lymphoma Innovation The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research. Learn more at . Media Contact, PreproMene Bio, Inc. John Fry, Executive Director Business Development [email protected] Media Contact, IFLI Laura DiCaprio McDougall Communications [email protected] +1 (585) 434-2153 SOURCE PeproMene Bio, Inc.; IFLI WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED